Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

MLA

de Bruin, Weller, M., et al. “Dupilumab with Concomitant Topical Corticosteroid Treatment in Adults with Atopic Dermatitis with an Inadequate Response or Intolerance to Ciclosporin A or When This Treatment Is Medically Inadvisable: A Placebo‐controlled, Randomized Phase III Clinical Trial (LIBERTY AD CAFÉ).” British Journal of Dermatology, vol. 178, no. 5, May 2018, pp. 1083–101. EBSCOhost, https://doi.org/10.1111/bjd.16156.

APA

de Bruin, W. M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., Hultsch, T., Chen, Z., Pirozzi, G., Graham, N. M. H., & Shumel, B. (2018). Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology, 178(5), 1083–1101. https://doi.org/10.1111/bjd.16156

Chicago

de Bruin, Weller, M., D. Thaçi, C. H. Smith, K. Reich, M. J. Cork, A. Radin, Q. Zhang, et al. 2018. “Dupilumab with Concomitant Topical Corticosteroid Treatment in Adults with Atopic Dermatitis with an Inadequate Response or Intolerance to Ciclosporin A or When This Treatment Is Medically Inadvisable: A Placebo‐controlled, Randomized Phase III Clinical Trial (LIBERTY AD CAFÉ).” British Journal of Dermatology 178 (5): 1083–1101. doi:10.1111/bjd.16156.